Briefly, the study involved following the microbes of pregnant women throughout pregnancy and a little while after childbirth. Participants were asked to provide samples from the mouth, skin, vagina and rectum. At select visits, participants were also asked to provide blood and urine samples. Women who enrolled answered questions about their health and other activities throughout the study. We also collected samples from both mothers and infants at birth and before discharge. More than 200,000 samples were collected through this project.
MOMS-PI is a multifaceted initiative that generated large and comprehensive datasets using several "omics" technologies: 1) 16S rRNA amplicon sequencing, 2) metagenome sequencing, 3) metatranscriptome sequencing, 4) metabolomics/lipidomics and 5) immunoproteomics/cytokine assays. Samples were collected throughout the course of pregnancy from a cohort of more than 1,500 women. Omics data generated from ~12,000 samples is avaiable through the HMP Data Coordination Center. We believe this large-scale, innovative effort will continue to lead to insights into how the microbiome impacts risk for preterm birth and the temporal dynamics of the pregnancy microbiome. Our analyses of these data is ongoing.
Funding: NIH (NICHD)U54HD080784 More than $10 M HMP Phase 2: The Integrative Human Microbiome Project (iHMP) Principal Investigators: Gregory A. Buck, Ph.D. Kimberly K. Jefferson, Ph.D. Jerome F. Strauss, III, M.D., Ph.D. Project Director: Jennifer M. Fettweis, Ph.D.
- What is the impact of pregnancy on the maternal microbiome?
- How does the microbiome effect maternal host response?
- How do the maternal host response and microbiome influence risk of preterm birth, early infant microbiome acquisition and neonatal health?
- What are the mechanisms by which the microbiome exerts effects on the female urogenital tract?